Prestige BioPharma Limited (KRX:950210)

South Korea · Delayed Price · Currency is KRW

6,780.00

-60.00 (-0.88%)

Aug 12, 2026, 1:40 PM KST

Prestige BioPharma Financials Overview

Financials in millions KRW. Fiscal year is July - June.

Millions KRW. Fiscal year is Jul - Jun.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	16,210	14,326	689.08	161.84	-	-
Revenue Growth	87.13%	1978.97%	325.77%	-	-	-
Gross Profit	-16,083	-12,237	-10,602	127.9	-228.95	-284.85
Operating Income	-83,868	-66,585	-62,238	1,034	-122,689	-18,384
Net Income	-57,321	22,297	-32,921	17,569	-211,450	-7,391
Earnings Per Share	-953.45	370.20	-549.00	292.35	-3796.17	-143.23
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Cash & Investments	65,894	173,712	222,492	301,412	303,270	459,353
Total Debt	88,812	144,179	89,667	115,561	4,249	7,771
Net Cash (Debt)	-22,917	29,533	132,825	185,851	299,020	451,582
Net Cash Growth	-	-77.77%	-28.53%	-37.85%	-33.78%	892.04%
Net Cash Per Share	-381.20	490.33	2215.00	3092.56	4975.70	8751.18

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Cash Flow	-41,214	-52,135	-48,027	-60,274	-45,907	-15,446
Capital Expenditures	-16,321	-40,742	-20,063	-48,363	-56,429	-949.11
Free Cash Flow	-57,535	-92,877	-68,091	-108,636	-102,336	-16,396
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Gross Margin	-99.22%	-85.42%	-	79.03%	-	-
Operating Margin	-517.38%	-464.80%	-9032.13%	639.01%	-	-
Pretax Margin	-493.59%	27.38%	-7936.63%	-1294.78%	-	-
Profit Margin	-353.62%	155.64%	-4777.60%	10855.90%	-	-
FCF Margin	-354.94%	-648.33%	-9881.47%	-67125.45%	-	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 12, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
PE Ratio	-	7.92	-	6.47	-	-
Forward PE	-	12.01	12.01	12.01	12.01	-
PS Ratio	5.07	12.33	150.88	701.81	-	-